EU Health Innovation
30 Einträge
Mo., 2. März 2026
EMA Backs First Combined COVID-19 and Flu Vaccine
Citizens over 50 may soon receive protection against both flu and COVID-19 with just one shot.
Mi., 4. März 2026
EMA Recommends 12 New Medicines for EU Approval
EMA recommends 12 new treatments, including options for rare and paediatric diseases.
So., 8. März 2026
New EU Guidance for Clinical Trials During Emergencies
New EU rules to ensure quicker, safer clinical trials during health crises.
Mi., 11. März 2026
EMA Issues Guidance on Clinical Trials
New EU guidance aims to improve clinical trial conduct during health crises.
Do., 12. März 2026
New EU Reference Labs for Public Health Announced
EU bolstering public health infrastructure by designating specialized reference labs.
Fr., 13. März 2026
EDPB & EDPS on harmonising clinical trials
Data protection watchdogs call for safeguards in harmonizing clinical trials.
Sa., 14. März 2026
EDPB Supports Biotech Act, Seeks Health Data Safeguards
EU data watchdogs push for strong data protection in biotech research.
So., 15. März 2026
EU Reference Labs for Public Health - Open Calls
New EU Reference Labs will improve public health and diagnostic testing standards across the EU.
Mo., 16. März 2026
EMA Highlights from March PRAC Meeting
Safety update on chikungunya vaccine: risk of aseptic meningitis.
Di., 17. März 2026
Joint Opinion on European Biotech Act Proposal
EU data protection watchdogs want safeguards for health data in Biotech Act.
Mi., 18. März 2026
EDPB Supports Biotech Act with Data Safeguards
Stronger data protection requested for health data in EU Biotech Act.
Do., 19. März 2026
EMA Introduces New PRIME Tools for Medicines
EMA enhances PRIME scheme to speed up development of medicines for unmet needs
Fr., 20. März 2026
EMA: New Medicines Development Tools
Faster development of innovative EU medicines
Sa., 21. März 2026
New PRIME Tools to Accelerate Development of Medicines in the EU
Di., 24. März 2026
EMA: New Tools to Speed Medicine Development
EMA boosts medicine development for unmet needs with new PRIME tools.
Sa., 28. März 2026
EMA Restricts Use of Tecovirimat SIGA
Mpox treatment faces restriction due to updated clinical data.
So., 29. März 2026
EMA Recommends New Lung Cancer Treatment
New lung cancer treatment gets EMA nod, expanding therapy options.
Mi., 1. Apr. 2026
EMA: New treatment for relapsed lung cancer approved
New treatment option becomes available for relapsed small cell lung cancer patients.
Do., 2. Apr. 2026
EMA Consults on Reducing Animal Use in Drug Development
New EMA consultation seeks to reduce animal use in preclinical drug research.
Do., 2. Apr. 2026
EMA consults on reducing animal use
EMA consults on methodology to reduce animal testing for new medicines.
Fr., 3. Apr. 2026
ECDC Reviews Latvia's Leptospirosis Response
Improving EU preparedness for waterborne disease outbreaks, future responses will be faster.
Fr., 3. Apr. 2026
ECDC supports Latvia leptospirosis outbreak review
Improving EU preparedness for leptospirosis and other outbreaks through lessons learned.
So., 5. Apr. 2026
Lung Cancer: New Treatment Approved in the EU
New treatment offers hope for relapsed lung cancer patients in EU.
So., 5. Apr. 2026
New Lung Cancer Treatment Recommended by EMA
EMA recommends new lung cancer treatment, offering hope for patients in the EU.
Mo., 6. Apr. 2026
EMA Consults on Virtual Control Groups
EMA consults on methodology to reduce animal use in medicine development.
Di., 7. Apr. 2026
ECDC Supports Latvia's Leptospirosis Review
ECDC supports Latvia in improving its response to waterborne disease outbreaks.
Di., 7. Apr. 2026
ECDC Supports Latvia Leptospirosis Review
ECDC helping Latvia improve its response to leptospirosis outbreaks.
Fr., 10. Apr. 2026
ECDC & Africa CDC Pilot Mobile App for Surveillance
ECDC partners with Africa CDC on mobile app to boost disease surveillance and response.
Sa., 11. Apr. 2026
EMA Consults on Reducing Animal Testing
EMA seeks to reduce animal testing by using virtual control groups in drug development.
Sa., 2. Mai 2026
EU Agencies Highlight Research Role in Policy-Making
EU policies will be more science-backed, leading to better citizen outcomes.
The EU is actively fostering health innovation through a multi-pronged approach. The European Medicines Agency (EMA) is pivotal, recently recommending the marketing authorization for Imdylltra, a new treatment for lung cancer, offering new hope for patients. Concurrently, the EMA is consulting on the use of virtual control groups to reduce animal testing in drug development, reflecting ethical considerations and scientific advancement. The European Centre for Disease Prevention and Control (ECDC) is strengthening global health security, partnering with Africa CDC to pilot a mobile app for disease surveillance and supporting Latvia in reviewing its response to the 2025 leptospirosis outbreak.
These efforts matter significantly for both citizens and businesses. Citizens benefit from faster access to innovative treatments, improved public health protection through enhanced disease surveillance, and policies backed by robust scientific evidence, as highlighted by the EU Agencies Network on Scientific Advice (EU-ANSA). Businesses in the pharmaceutical sector are encouraged to adopt innovative and ethical research methodologies, like reduced animal testing, while engaging in collaborative efforts that drive market authorization for novel therapies.
Looking ahead, this direction points towards a more agile, scientifically-driven, and ethically conscious health innovation ecosystem in the EU. The focus will remain on leveraging technology for public health preparedness, as seen with the mobile app pilot, and continually refining regulatory processes to accelerate the availability of cutting-edge treatments. The commitment to evidence-based policy-making will ensure that future health strategies are responsive to emerging threats and opportunities, ultimately enhancing the well-being of EU citizens.